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Abstract 
Background: Chemoresistance is a major obstacle to successful chemotherapy for colorectal cancer. Eukaryotic 
translation initiation factor 5A2 (eIF5A2), one of the two isoforms in the eIF5A family, has been reported to be a 
new oncogene in many types of human cancer. In the present study, we aimed to investigate whether eIF5A2 was 
involved in the chemoresistance to doxorubicin in colorectal cancer.
Methods: Cell viability was measured by CCK-8 assay with or without doxorubicin treatment. Protein expression was 
detected by western blot. Tumor cells were transfected with eIF5A2 siRNA or plasmid encoding eIF5A2 to down- or 
up regulate the expression of eIF5A2.
Results: We found that eIF5A2-negtive colon cancer cells (HCT116 and HT29) were more sensitive to doxorubicin 
compare with the eIF5A2-positive cells (LOVO and SW480). Downregulation of eIF5A2 in LOVO and SW480 cells 
enhanced the chemosensitivity to doxorubicin. On the contrary, overexpression of eIF5A2 reduced doxorubicin 
sensitivity in colon cancer cells. In addition, eIF5A2 knockdown increased the protein level of E-cadherin and reduced 
vimentin expression in LOVO and SW480 cells. Meanwhile, upregulation of eIF5A2 potentiated epithelial mesenchy-
mal transition (EMT) in colon cancer cells. Moreover, blockade of EMT with Twist siRNA abolished eIF5A2-regulated 
chemoresistance in colon cancer cells.
Conclusion: Our present study demonstrated that eIF5A2 promoted the chemoresistance to doxorubicin via regula-
tion of EMT in colon cancer cells. Therefore, eIF5A2 inhibition may be a new potential strategy for the reversal of drug 
resistance in colorectal cancer therapy.
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Background
Colorectal cancer is the second most common cancer in 
the United States, and its incidence has been increasing 
in developing countries [1, 2]. It is estimated that over 
1 million new cases are diagnosed each year worldwide, 
and approximately 50 % of these patients die of colorectal 
cancer [3]. Currently, surgical resection is the opti-
mal treatment for colorectal cancer, and chemotherapy 
serves as one of the important adjuvant therapies for its 
treatment [4]. However, the development of acquired 
drug resistance to conventional chemotherapeutics has 
become a major obstacle in colorectal cancer treatment 
[5, 6]. Such limitation highlights the imperative need 
for identifying novel treatment strategies which may 
help overcome drug resistance and enhance tumor cell 
response to anti-cancer drugs.
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It is generally believed that carcinogenesis and devel-
opment of colorectal cancer comprises a series of com-
plicated processes regulated by aberrantly protein 
expression and alterations of morphological features 
during malignant progression [7–9]. The term epithelial-
mesenchymal transition (EMT) refers to the complicated 
progress in which tumor cell loses epithelial proper-
ties and gains mesenchymal morphology with capacity 
for metastasis [10, 11]. EMT is involved in wound heal-
ing, stem cell behaviour, development, and contributes 
to cancer progression [12–14]. Emerging evidence sug-
gests that EMT also plays a critical role in the regula-
tion of chemoresistance properties of cancer cells [15, 
16]. Eukaryotic translation initiation factor 5A2 (eIF5A2) 
mainly acts as an elongation factor during mRNA trans-
lation step. It has been identified as an oncogene in ovar-
ian cancer, suggesting that aberrant expression of eIF5A2 
may be responsible for the malignant behavior of can-
cer cells [17–19]. However, the relationship of eIF5A2 
and drug resistance in colorectal cancer has never been 
explored. Hence, the present study aimed to investi-
gate the biological role of eIF5A2 in colorectal cancer 
chemoresistance.
Results
Different doxorubicin sensitivity in colon cancer cells
Firstly, CCK-8 assay was performed to measure the sensi-
tivity of different colon cancer cell lines (HCT116, HT29, 
LOVO and SW480) to doxorubicin. We found that doxo-
rubicin sensitivity varied among cell lines (Fig. 1a, b). As 
shown in Table 1, the IC50 values were significantly higher 
in LOVO and SW480 cells (0.7810 and 0.5227  μg/mL, 
respectively) than in HCT116 and HT29 cells (0.1238 
and 0.03659  μg/mL, respectively). Specifically, SW480 
cells were more sensitive to doxorubicin compared with 
LOVO cells (Fig. 1b). Western blot analysis demonstrated 
that eIF5A2 was expressed in LOVO and SW480 cells 
but no in HCT116 and HT29 cells (Fig. 1c). Interestingly, 
we observed the highest expression of eIF5A2 in LOVO 
cells, which were the most insensitive colon cancer cells 
to doxorubicin. These results implied that eIF5A2 may be 
involved in the chemoresistance of colon cancer cells.
Downregulation of eIF5A2 sensitized colon cancer cells 
to doxorubicin
In order to confirm that eIF5A2 participated in chemore-
sistance to doxorubicin, eIF5A2 siRNA was transfected 
Fig. 1 Different doxorubicin sensitivity in colon cancer cells. Four human colon cancer cell lines including HCT116, HT29 (a), and LOVO, SW480 
(b) were incubated with doxorubicin for 48 h. Cell viability was measured using CCK-8 method. Western blot was performed to determine eIF5A2 
expression in HCT116, HT29, LOVO and SW480 cells (c). *P < 0.05, compared with LOVO; #P < 0.05, compared with SW480
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into LOVO and SW480 cells. We found that downregu-
lation of eIF5A2 enhanced doxorubicin sensitization in 
LOVO (Fig.  2a) and SW480 (Fig.  2b) cells. In addition, 
western blot analysis indicated that eIF5A2 knockdown 
promoted the expression of E-cadherin and reduced 
vimentin expression in LOVO and SW480 cells (Fig. 2c). 
These results demonstrated that downregulation of 
eIF5A2 prevented EMT and restored doxorubicin sensi-
tivity in colon cancer cells.
eIF5A2 overexpression reduced doxorubicin sensitivity 
in colon cancer cells
Next we transfected colon cancer cell lines with plas-
mids encoding eIF5A2 to investigate the effect of eIF5A2 
overexpression on tumor cells response to drugs. For 
eIF5A2-positive cells, upregulation of eIF5A2 reduced 
the sensitivity to doxorubicin in LOVO (Fig.  3a) and 
SW480 (Fig. 3b) cells. In addition, eIF5A2 overexpression 
also significantly suppressed the doxorubicin sensitivity 
in eIF5A2-negative cells, i.e. HCT116 (Fig. 3c) and HT29 
(Fig. 3d) cells.
Effect of eIF5A2 overexpression on tumor cell phenotype
We further investigated why eIF5A2 overexpression 
reduced doxorubicin sensitivity in colon cancer cells. 
We considered the possibility that cell phenotype 
changes may cause the different responses of colon can-
cer cell lines to doxorubicin. Not surprisingly, eIF5A2 
upregulation significantly reduced the expression of 
E-cadherin and enhanced vimentin expression in the 
four colon cancer cell lines (Fig.  4). In addition, Twist 
siRNA (a critical regulator in EMT) and eIF5A2 plas-
mid/eIF5A2 siRNA were co-transfected into tumor 
cells followed by determination of cell viabilities in 
HCT116, HT29, LOV0 and SW480 cells. Result showed 
that blockade of EMT with Twist siRNA abolished 
the regulatory effects of eIF5A2 on cancer cell chem-
oresistance to doxorubicin, suggesting that EMT was 
mainly responsible for eIF5A2-mediated chemoresist-
ance (Fig. 5). These findings suggested that regulation of 
EMT was responsible for eIF5A2-mediated doxorubicin 
sensitivity in colon cancer cells.
Table 1 IC50 values of doxorubicin in colorectal cancer cell 
lines





Fig. 2 Downregulation of eIF5A2 sensitized colon cancer cells to doxorubicin. CCK-8 assay was performed to measure the cell viability of LOVO (a) 
and SW480 (b) after transfection with eIF5A2 siRNA or control siRNA. Western blot analysis of E-cadherin and Vimentin expression in eIF5A2 siRNA 
or control siRNA transfected colon cancer cells. Relative protein expression in LOVO and SW480 cells was quantified by band density with GAPDH 
served as control (c). *P < 0.05
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Discussion
As an important adjuvant treatment, chemotherapy 
serves as an necessary component of postoperative ther-
apy for colorectal cancer [20]. However, most traditional 
chemotherapeutic drugs leads to drug resistance and this 
has become a major obstacle to the triumph of chemo-
therapy [21]. Therefore, it is imperative to identify novel 
therapeutic targets which are involved in the acquisition 
of drug resistance. In this study, we demonstrated that 
eIF5A2 was associated with the chemoresistance to dox-
orubicin in colorectal cancer cells.
eIF5A2, an essential component of translation elonga-
tion, has been identified to be a novel oncogenic protein 
in many types of human cancer [17, 18]. Upregulation 
of eIF5A2 has been reported in many cancers including 
ovarian cancer, hepatocellular carcinoma, and bladder 
cancer [22–24]. Both in vitro and in vivo studies suggest 
that eIF5A2 could promote cancer cell proliferation and 
increase cancer cell metastasis [22]. Furthermore, it is 
suggested that eIF5A2 may serve as prognostic biomarker 
for poor survival of hepatocellular carcinoma patients 
[25]. In a recent study, eIF5A2 was found to be up-reg-
ulated in colorectal cancer patients, and it was suggested 
to be an independent predictor of shortened survival 
[26]. Moreover, eIF5A is considered as a potential ther-
apeutic target in many human disorders. In HT-29 and 
HeLa cells, eIF5A can induce p53-independent apop-
tosis through mitochondrial pathway [27]. In our study, 
we found that eIF5A2-negative colon cancer cells were 
more sensitive to doxorubicin compare with the eIF5A2-
positive cells. Thus we hypothesized that eIF5A2 may 
play an important role in the chemoresistance of colon 
cancer cells. To test this hypothesis, eIF5A2 siRNA was 
transfected into LOVO and SW480 cells and we observed 
enhanced chemosensitivity to doxorubicin. Moreover, 
eIF5A2 overexpression reduced doxorubicin sensitivity 
in colon cancer cells. Taken together, these results dem-
onstrated that eIF5A2 promoted the chemoresistance to 
doxorubicin in colon cancer cells.
It is generally believed that tumorigenesis is a multi-
step process regulated by aberrantly protein expression 
and alterations of morphological and molecular features 
during malignant progression [28]. One such change is 
the loss of epithelial property and gain of mesenchymal 
morphology, which suggests the initiation of EMT [29]. 
Accumulating evidences suggest that EMT plays crucial 
Fig. 3 eIF5A2 overexpression reduced doxorubicin sensitivity. eIF5A2 plasmids were transfected into LOVO (a), SW480 (b), HCT116 (c) and HT29 (d) 
cells. 48 h after transfection, CCK-8 assay was performed to measure cell viability in the presence of doxorubicin
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roles in the acquired chemoresistance in many kinds of 
cancer, including colorectal cancer [30–32]. Thus, we 
investigated whether eIF5A2 was involved in regulation 
of the EMT during the chemoresistance to doxorubicin. 
Intriguingly, our results demonstrated that overexpres-
sion of eIF5A2 significantly decreased the protein level 
of E-cadherin and increased vimentin expression in 
HCT116, HT29, LOVO and SW480 cells. On the con-
trary, downregulation of eIF5A2 reversed the EMT in 
LOVO and SW480 cells. Furthermore, we found that 
blockade of EMT with Twist siRNA abolished eIF5A2-
regulated chemoresistance. These findings suggested that 
regulation of EMT was mainly responsible for eIF5A2-
mediated doxorubicin sensitivity in colon cancer cells.
In conclusion, our study demonstrated that eIF5A2 
promoted the chemoresistance to doxorubicin through 
regulation of EMT in colon cancer cells. Moreover, spe-
cific downregulation of eIF5A2 could reverse the EMT 
and enhance chemosensitivity to doxorubicin in colon 
cancer cells. Our study provided a new potential strategy 
Fig. 4 eIF5A2 overexpression altered tumor cell phenotype. Western blot analysis of E-cadherin and Vimentin expression in eIF5A2 siRNA or control 
siRNA transfected colon cancer cells. Relative protein expression in LOVO, SW480, HCT116 and HT29 cells was quantified by band density with 
GAPDH served as control. *P < 0.05
Page 6 of 7Bao et al. Cancer Cell Int  (2015) 15:109 




Human colon cancer cell lines HCT116, HT29, LOVO 
and SW480 were purchase d from the ATCC (Manas-
sas, VA, USA) and cultured in DMEM (Gibco, Carls-
bad, CA, USA) supplemented with 10  % FBS and 1  % 
penicillin⁄streptomycin. All cells were maintained at 37 °C 
in 5 % CO2 incubator.
Cell viability assay
Tumor cells were seeded onto 96-well plates at 3 ×  103 
cells⁄well. The medium was replaced with the corre-
sponding serum-free medium for 24 h, then serum-free 
medium was replaced with complete medium containing 
the drugs at the indicated doses for 48 h. Then 10 µL⁄well 
CCK-8 solution (Dojindo, Kumamoto, Japan) was added 
and incubated with the plates for 3 h, and the absorbance 
was determined at 450 nm using an MRX II microplate 
reader (Dynex, Chantilly, VA, USA).
Transfection
Tumor cells were transfected with eIF5A2 siRNA, eIF5A2 
siRNA or plasmid encoding eIF5A2 using Lipofectamine 
2000 (Invitrogen, USA) according to the manufactur-
er’s instruction. The transfection medium (Opti-MEM; 
Gibco, USA) was replaced with complete medium 12  h 
after transfection, and the cells were incubated for the 
indicated times.
Western blot analysis
Tumor cells were lysed in 50  μL cell lysis buffer (Cell 
Signaling, Danvers, MA, USA) containing protease inhib-
itors (Sigma, USA). Whole cell lysates were prepared 
and fractioned were separated by 10  % SDS-PAGE and 
proteins were transferred to polyvinylidene difluoride 
(PVDF) membranes (Millipore, Billerica, MA, USA). The 
membranes were then incubated with primary antibodies 
Fig. 5 EMT inhibition abolished the role of eIF5A2 on chemoresistance. Twist siRNA and eIF5A2 plasmid were co-transfected into HCT116 and HT29 
cells, and Twist siRNA and eIF5A2 siRNA were transfected into LOV0 and SW480 cells. Western blot and CCK-8 assay were performed to measure the 
protein expression and cell viability, respectively
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(E-cadherin, Vimentin or eIF5A2, diluted 1:1000; Abcam, 
Cambridge, USA) at 4  °C overnight. The membranes 
were washed three times with TBST and then incubated 
with the appropriate HRP-conjugated secondary anti-
bodies for 1  h at room temperature. Protein expression 
was detected by chemiluminescence (GE Healthcare, Pis-
cataway, NJ, USA).
Statistical analysis
Each experiment was performed in triplicate, and 
repeated at least three times. All the data were presented 
as mean ± SD and treated for statistics analysis by SPSS 
program. Comparison between groups was made using 
ANOVA and statistically significant difference was 
defined as P < 0.05.
Authors’ contributions
YB designed this project, YLL, XW, and WMF written this paper, XRS and HHG 
conduct the western blot analysis, CWT and XJZ performed the statisti-
calstudy, QLS and HBY performed the cell culture and viability assay. All 
authorsread and approved the final manuscript.
Author details
1 First Affiliated Hospital, Huzhou Teachers College, The First People’s Hospital 
of Huzhou, 158 Guangchanghou Road, 313000 Huzhou, China. 2 Huzhou 
Teachers College of Medicine, 313000 Huzhou, China. 
Acknowledgements
This study was supported by Zhejiang Natural Science Foundation 
(LY16H160040 and LY16H160041), Huzhou key projects of public wel-
fare (2014GZ11), Zhejiang applied research projects of public welfare 
(2014C33245).
Competing interests
The authors declare that they have no competing interests.
Received: 17 June 2015   Accepted: 5 October 2015
References
 1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 
2013;63:11–30.
 2. Rehman MU, Buttar QM, Khawaja MI, et al. An impending cancer crisis in 
developing countries: are we ready for the challenge? Asian Pac J Cancer 
Prev. 2009;10:719–20.
 3. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship 
statistics, 2012. CA Cancer J Clin. 2012;62:220–41.
 4. Chibaudel B, Tournigand C, Andre T, et al. Therapeutic strategy in unre-
sectable metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4:75–89.
 5. Kong Y, Bai PS, Sun H, et al. The deoxycholic acid targets miRNA-depend-
ent CAC1 gene expression in multidrug resistance of human colorectal 
cancer. Int J Biochem Cell Biol. 2012;44:2321–32.
 6. Yasunaga M, Matsumura Y. Role of SLC6A6 in promoting the survival and 
multidrug resistance of colorectal cancer. Sci Rep. 2014;4:4852.
 7. Martinez-Garcia R, Lopez-Casas PP, Rico D, et al. Colorectal cancer classifi-
cation based on gene expression is not associated with FOLFIRI response. 
Nat Med. 2014;20:1230–1.
 8. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer 
pathogenesis. Gastroenterology. 2010;138:2088–100.
 9. Kim PJ, Plescia J, Clevers H, et al. Survivin and molecular pathogenesis of 
colorectal cancer. Lancet. 2003;362:205–9.
 10. Grant CM, Kyprianou N. Epithelial mesenchymal transition (EMT) in pros-
tate growth and tumor progression. Transl Androl Urol. 2013;2:202–11.
 11. Chen D, Huang J, Zhang K, et al. MicroRNA-451 induces epithelial-mes-
enchymal transition in docetaxel-resistant lung adenocarcinoma cells by 
targeting proto-oncogene c-Myc. Eur J Cancer. 2014;50:3050–67.
 12. Kong D, Sethi S, Li Y, et al. Androgen receptor splice variants contribute to 
prostate cancer aggressiveness through induction of EMT and expression 
of stem cell marker genes. Prostate. 2015;75:161–74.
 13. Acharya A, Baek ST, Huang G, et al. The bHLH transcription factor Tcf21 
is required for lineage-specific EMT of cardiac fibroblast progenitors. 
Development. 2012;139:2139–49.
 14. Bates RC, Mercurio AM. The epithelial-mesenchymal transition (EMT) and 
colorectal cancer progression. Cancer Biol Ther. 2005;4:365–70.
 15. Ren J, Chen Y, Song H, et al. Inhibition of ZEB1 reverses EMT and chem-
oresistance in docetaxel-resistant human lung adenocarcinoma cell line. 
J Cell Biochem. 2013;114:1395–403.
 16. Rosano L, Cianfrocca R, Spinella F, et al. Acquisition of chemoresistance 
and EMT phenotype is linked with activation of the endothelin A recep-
tor pathway in ovarian carcinoma cells. Clin Cancer Res. 2011;17:2350–60.
 17. Yang GF, Xie D, Liu JH, et al. Expression and amplification of eIF-5A2 in 
human epithelial ovarian tumors and overexpression of EIF-5A2 is a new 
independent predictor of outcome in patients with ovarian carcinoma. 
Gynecol Oncol. 2009;112:314–8.
 18. Clement PM, Johansson HE, Wolff EC, et al. Differential expression of 
eIF5A-1 and eIF5A-2 in human cancer cells. FEBS J. 2006;273:1102–14.
 19. Guan XY, Fung JM, Ma NF, et al. Oncogenic role of eIF-5A2 in the develop-
ment of ovarian cancer. Cancer Res. 2004;64:4197–200.
 20. Mori T, Ohue M, Takii Y, et al. Factors predicting the response to oral fluo-
ropyrimidine drugs: a phase II trial on the individualization of postopera-
tive adjuvant chemotherapy using oral fluorinated pyrimidines in stage 
III colorectal cancer treated by curative resection (ACT-01 Study). Oncol 
Rep. 2013;29:437–44.
 21. Brown R, Curry E, Magnani L, et al. Poised epigenetic states and acquired 
drug resistance in cancer. Nat Rev Cancer. 2014;14:747–53.
 22. Tang DJ, Dong SS, Ma NF, et al. Overexpression of eukaryotic initiation 
factor 5A2 enhances cell motility and promotes tumor metastasis in 
hepatocellular carcinoma. Hepatology. 2010;51:1255–63.
 23. Guan XY, Sham JS, Tang TC, et al. Isolation of a novel candidate oncogene 
within a frequently amplified region at 3q26 in ovarian cancer. Cancer 
Res. 2001;61:3806–9.
 24. Wei JH, Cao JZ, Zhang D, et al. EIF5A2 predicts outcome in localised 
invasive bladder cancer and promotes bladder cancer cell aggressiveness 
in vitro and in vivo. Br J Cancer. 2014;110:1767–77.
 25. Lee NP, Tsang FH, Shek FH, et al. Prognostic significance and therapeutic 
potential of eukaryotic translation initiation factor 5A (eIF5A) in hepato-
cellular carcinoma. Int J Cancer. 2010;127:968–76.
 26. Zhu W, Cai MY, Tong ZT, et al. Overexpression of EIF5A2 promotes 
colorectal carcinoma cell aggressiveness by upregulating MTA1 through 
C-myc to induce epithelial-mesenchymaltransition. Gut. 2012;61:562–75.
 27. Sun Z, Cheng Z, Taylor CA, et al. Apoptosis induction by eIF5A1 involves 
activation of the intrinsic mitochondrial pathway. J Cell Physiol. 
2010;223:798–809.
 28. Delude C. Tumorigenesis: testing ground for cancer stem cells. Nature. 
2011;480:S43–5.
 29. Celia-Terrassa T, Meca-Cortes O, Mateo F, et al. Epithelial-mesenchymal 
transition can suppress major attributes of human epithelial tumor-
initiating cells. J Clin Invest. 2012;122:1849–68.
 30. Wang Z, Li Y, Ahmad A, et al. Targeting miRNAs involved in cancer stem 
cell and EMT regulation: an emerging concept in overcoming drug resist-
ance. Drug Resist Updat. 2010;13:109–18.
 31. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an 
emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–51.
 32. Bhangu A, Wood G, Mirnezami A, et al. Epithelial mesenchymal transition 
in colorectal cancer: seminal role in promoting disease progression and 
resistance to neoadjuvant therapy. Surg Oncol. 2012;21:316–23.
